Prospects for targeting PD-1 and PD-L1 in various tumor types

  • Kim J
  • Eder J
  • 74


    Mendeley users who have this article in their library.
  • 32


    Citations of this article.


Immune checkpoints, such as programmed death ligand 1 (PD-L1) or its receptor, programmed death 1 (PD-1), appear to be Achilles' heels for multiple tumor types. PD-L1 not only provides immune escape for tumor cells but also turns on the apoptosis switch on activated T cells. Therapies that block this interaction have demonstrated promising clinical activity in several tumor types. In this review, we will discuss the current status of several anti-PD-1 and anti-PD-L1 antibodies in clinical development and their direction for the future.

Author-supplied keywords

  • Antibodies
  • Antigens
  • CD274
  • CD274: analysis
  • CD274: antagonists & inhibitors
  • Carcinoma
  • Drug Resistance
  • Humanized
  • Humanized: therapeutic use
  • Humans
  • Kidney Neoplasms
  • Kidney Neoplasms: drug therapy
  • Melanoma
  • Melanoma: drug therapy
  • Melanoma: secondary
  • Monoclonal
  • Monoclonal: therapeutic use
  • Neoplasm
  • Neoplasms
  • Neoplasms: drug therapy
  • Programmed Cell Death 1 Receptor
  • Programmed Cell Death 1 Receptor: analysis
  • Programmed Cell Death 1 Receptor: antagonists & in
  • Small Cell
  • Small Cell: drug therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Joseph W Kim

  • Joseph Paul Eder

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free